Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Food Archives
Print | Email | Share | Comments (3)

How Diabetes Topics in the News Can Start to Feel Like a Game of “Telephone”

Oct 27, 2008

Diabetes Health writer Patrick Totty wonders if the Byetta “controversy” is largely a media creation. Has the threshold for controversy these days stooped so low to reach so high?

A recent Wall Street Journal article shows once again how misinformation about diabetes-related topics can be spread by even the most expert journalists.

The article, headlined "Eli Lilly to Pay for Right to Sell Diabetes Treatment Outside U.S.," begins, "Eli Lilly & Co. will pay Amylin Pharmaceuticals Inc. for the right to sell a controversial diabetes treatment outside of the U.S." (our italics)

The article discusses Lilly purchasing the right to sell a long-acting form of Byetta outside of the United States. Byetta, the brand name for exenatide, has approximately 700,000 users in the United States. Introduced in 2005, it is a proven means of controlling blood sugar levels in people with diabetes and helping many of them lose weight.

The version Lilly will sell abroad, called Byetta LAR and taken once weekly, is now undergoing the approval process by the U.S. Food and Drug Administration. 

The article jumps the track when it notes that when Amylin reported that Byetta performed well against a rival drug, Januvia, "that news came after recent reports of deaths from severe pancreatitis in patients on currently marketed twice-daily doses of Byetta. Amylin has repeatedly stated there is no proven relationship between Byetta and pancreatic side effects."

Those two sentences are the vaunted "balance" that journalists always talk about when they write a "he said/she said" piece.

Here's the problem with it:

  • The source of the "recent reports"-the FDA-is never identified.
  • The number of deaths from severe pancreatitis in patients taking Byetta is not mentioned (six).
  • The number of people taking Byetta who have also experienced severe, but not fatal, pancreatitis is not mentioned (30).
  • The total number of people taking Byetta is never mentioned (approx. 700,000).
  • The difference between correlation (taking Byetta and later getting severe pancreatitis) and causation (taking Byetta and therefore getting severe pancreatitis) is never mentioned or explored. 

Admittedly, the article's writer was probably facing space constraints and had to resort to the shorthand explanation above. The problem with that shorthand is it soon becomes an accepted stand-in for more thoughtful and thorough explanations of controversial topics.  

In fact, the "controversy" is largely a media creation. Even if Byetta could be proven as the cause of six fatal cases of pancreatitis among several hundred thousand users over a three-year period, we are talking about roughly one in every 116,000 users. 

Is the threshold for controversy these days that low?

Disclaimer: Contributing writer Patrick Totty has type 2 diabetes and takes metformin and a sulfonylurea. He has never taken Byetta. He has no investments in and no personal or professional relations with Amylin or Lilly. He dislikes junk science and hates to see it repeated in a good newspaper like the Wall Street Journal.



Categories: Blood Sugar, Byetta, Community, Diabetes, Diabetes, Food, Losing weight, Politics, Type 2 Issues



You May Also Be Interested In...


Comments

Posted by Anonymous on 28 October 2008

Good article. One point to keep in mind is that this is not unusual for the media. This is not to make an excuse for them, but it is fairly standard operating mode even in writing about non-technical topics.

Posted by PlelpexCenkip on 18 March 2009

Just a test.
ooze-grounded a test. get hold of bumf on newborn babe nourish, cradle caps, babe paste mindfulness and other parenthood and rearing resources from . test

Posted by jaiffPeevecar on 13 April 2009

Hi!

Where can i read more about indian pharmacy

Weight Loss treatment?


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.